Local innovative pharmaceutical research and development company released two phase clinical trial data of hepatitis C new drug ASC08

Dr Wu Jinzi, President and CEO of Hangzhou Song Li Biotechnology (Hangzhou) Co., Ltd delivered a speech China's indigenous innovation and drug research and development company today announced its direct anti Direct (Agent) Data of phase II clinical trial of asc08 was released in the form of special theme report by the president of the conference at the 24th Annual Meeting of the Asia Pacific Society of Hepatology on March 13 According to the results of the second phase clinical study named dapsang, after 12 weeks of treatment, the cure rate (svr12) of patients with genotype 1 non cirrhosis in Taiwan was 94%, while that of patients with genotype 1b non cirrhosis was 100% Professor Gao Jiahong, principal researcher of dapsang, director of Clinical Medicine Research Institute of Medical College of Taiwan University and chief physician of hepatitis research center of Taida hospital, reported the results at the annual meeting "The results show that compared with gene 1a The treatment regimen of asc08 combined with pegylated interferon α - 2A and ribavirin in Caucasian chronic hepatitis C patients with genotype 1b has shown a higher cure rate in Chinese chronic hepatitis C patients with genotype 1b, "said Professor Gao Jiahong." these data provide a strong safety and effectiveness for further confirmatory clinical research in mainland China Evidence " At the annual meeting of the Asia Pacific Society for the study of liver diseases, there were three leading edge hepatitis C drugs, asc08 (danoprevir) of Geli, sofosbuvir of Gilead and beclabuvir of Bristol Myers Squibb "It's a great honor for dapsang's research results to be highly valued and affirmed by the Asia Pacific hepatology Research Association," said Dr Wu JINZI, President and CEO of Geli "We are very pleased to share this major achievement in" national liver loving day ", which is comparable to the international leading-edge hepatitis C drugs on the market Since there is no direct anti HCV drug in the Chinese market at present, the release of this achievement marks a great step forward for asc08 to provide a new and effective treatment scheme for the vast number of Chinese hepatitis C patients " About the genotype of hepatitis C virus in China: Professor Wei Lai, vice president of the people's Hospital of Peking University and director of the Institute of Hepatology of Peking University, led the investigation and Research on hepatitis C virus and human genes The results showed that in China, the patients with genotype 1b accounted for 98% of genotype 1 and 57% of all hepatitis C patients About Geli: Geli is a local pharmaceutical enterprise based in China and facing the world Geli is committed to the discovery, development and commercialization of new infectious diseases and cancer drugs Geli is composed of entrepreneurial management and research returnees Up to now, Geli has four candidate drugs in clinical stage: asc08 (danoprevir), asc16 (ppi-668), asc06 (AlN – VSP) and asc09 (tmc310911), which are the inhibitors of HCV NS3 / 4A and RNAi For more information, please visit our website www.ascletis.com (outside China) and www.ascletis.com.cn (China) about APASL: APASL is the highest academic institution in the region, and is listed as the world's three major academic research organizations together with American hepatology society and European hepatology society The Asia Pacific Annual Meeting of liver diseases is held once a year Before that, Chinese scholars successfully held the 20th Asia Pacific Annual Meeting of liver diseases in Beijing in 2010 The Asia Pacific Society for the study of liver diseases aims to promote academic exchanges and cooperation in various regions, and has become one of the highest academic exchange platforms in the Asia Pacific region Website of the 24th APASL annual meeting: http://www.apasl2015.org about asc08: up to now, asc08 has carried out 34 phase I and phase II clinical trials in Europe, America and Asia (including Taiwan, China), which were included in about 2400 subjects in the group The results showed that the safety of asc08 combined with pegylated interferon α - 2A and ribavirin in the treatment of chronic hepatitis C patients was the same as that of standard therapy, but the cure rate was significantly improved, and the treatment course was reduced from 48 weeks to 12 weeks It is particularly important that asc08 combined with peginterferon α - 2A and ribavirin has a higher cure rate in Chinese chronic hepatitis C patients with genotype 1b than in Caucasian chronic hepatitis C patients with genotype 1a , about dapsang: Dapsang study is a phase II clinical study in patients with newly treated chronic hepatitis C (CHC) with HCV gene 1 Patients from Taiwan, Thailand and South Korea were enrolled in this study Two groups were set up in the study, one was non cirrhosis group (group A) and the other was cirrhosis group (Group B) All patients received the combination standard of asco08 (danoprevir) strengthened by ritonavir (RTV) The treatment period of patients with non cirrhosis was 12 weeks, and that of patients with cirrhosis was 24 weeks The main end point of the study was svr12 In this study, 61 patients were selected, 34 in group A (17 in Taiwan), 27 in group B (11 in Taiwan) After the treatment of asc08 combined with PEG-IFN and RBV, Asian patients with HCV genotype 1 infection in newly treated non cirrhotic patients (group A) got high svr12 (88.2%); among them, patients with HCV genotype 1b got higher svr12 (96.7%) In group A, patients with HCV genotype 1 infection in Taiwan got higher svr12 (94.1%) than those in the whole Asian population, among which patients with HCV genotype 1b got the best svr12 (100%) Asian patients with HCV genotype 1 infection had higher svr12 (88.9%) than those with HCV genotype 1b infection (91.7%) In group B, patients with HCV genotype 1 infection in Taiwan also obtained high svr12 (90.9%); among them, patients with HCV genotype 1b obtained the same svr12 (90.9%).